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Background: This study examined the prevalence of hypogonadism, its clinical and genetic risk 
factors, and its relationship to adverse health outcomes (AHOs) in North American testicular 
cancer survivors (TCS) after modern platinum-based chemotherapy.
Patients and Methods: Eligible TCS were <55 years of age at diagnosis and treated with first-
line platinum-based chemotherapy. Participants underwent physical examinations and completed 
questionnaires regarding 15 AHOs and health behaviors. Hypogonadism was defined as serum 
testosterone levels ≤3.0 ng/mL or use of testosterone replacement therapy. We investigated the role 
of 2 single nucleotide polymorphisms (rs6258 and rs12150660) in the sex hormone-binding 
globulin (SHBG) locus implicated in increased hypogonadism risk in the general population.
Results: Of 491 TCS (median age at assessment, 38.2 years; range, 18.7–68.4 years), 38.5% had 
hypogonadism. Multivariable binary logistic regression analysis identified hypogonadism risk 
factors, including age at clinical evaluation (odds ratio [OR], 1.42 per 10-year increase; P=.006) 
and body mass index of 25 to <30 kg/m2 (OR, 2.08; P=.011) or ≥30 kg/m2 (OR, 2.36; P=.005) 
compared with <25 kg/m2. TCS with ≥2 risk alleles for the SHBG SNPs had a marginally 
significant increased hypogonadism risk (OR, 1.45; P=.09). Vigorous-intensity physical activity 
appeared protective (OR, 0.66; P=.07). Type of cisplatin-based chemotherapy regimen and 
socioeconomic factors did not correlate with hypogonadism. Compared with TCS without 
hypogonadism, those with hypogonadism were more likely to report ≥2 AHOs (65% vs 51%; P=.
003), to take medications for hypercholesterolemia (20.1% vs 6.0%; P<.001) or hypertension 
(18.5% vs 10.6%; P=.013), and to report erectile dysfunction (19.6% vs 11.9%; P=.018) or 
peripheral neuropathy (30.7% vs 22.5%; P=.041). A marginally significant trend for increased use 
of prescription medications for either diabetes (5.8% vs 2.6%; P=.07) or anxiety/depression 
(14.8% vs 9.3%; P=.06) was observed.
Conclusions: At a relatively young median age, more than one-third of TCS have 
hypogonadism, which is significantly associated with increased cardiovascular disease risk factors, 
and erectile dysfunction. Providers should screen TCS for hypogonadism and treat symptomatic 
patients.
Background
Testicular cancer is the most common cancer among young men (age 18–39 years).1 
Currently, >95% of patients are cured of the disease.2 Although some patients with stage I 
disease are cured with orchiectomy only, those with advanced or recurrent disease will 
typically require cisplatin-based chemotherapy. Although testicular cancer survivors (TCS) 
can now expect to live for >40 years after diagnosis,3 they are at risk for short-and long-term 
complications related to cancer therapy, including hypogonadism.4
Hypogonadism and its health effects have been largely studied in the general population in 
older men, because testosterone levels decrease with aging.5–8 Hypogonadism has been 
linked to obesity, high cholesterol levels, cardiovascular disease (CVD), and decreased bone 
mineral density.9,10 Recent genetic investigations in the general population have identified 2 
single nucleotide polymorphisms (SNPs) in the sex hormone-binding globulin gene (SHBG) 
through genome-wide association studies associated with increased risk for hypogonadism.
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 No study, however, has examined the prevalence of hypogonadism in North American 
TCS and its relationship to adverse health outcomes (AHOs).
Most TCS have had one testicle (or both) surgically removed and have received 
chemotherapy that can damage the function of the remaining testicle, and thus are already at 
elevated risk for hypogonadism compared with the general population. In addition, an 
inherently increased risk may be due to testicular dysgenesis syndrome, a constellation of 
conditions proposed to also elevate risk of testicular cancer.12–14
This study examined the prevalence of AHOs in relationship to hypogonadism among TCS 
enrolled in the Platinum Study, a multicenter North American investigation of the long-term 
effects of cisplatin-based chemotherapy. The role of SHBG gene polymorphisms in 
hypogonadism risk among TCS are also investigated for the first time.
Patients and Methods
Participants
The Platinum Study protocol evaluated late consequences of platinum-based chemotherapy 
and was approved by the Institutional Review Boards at all participating institutions.15 Each 
study participant provided written informed consent allowing access to their medical records 
since their cancer diagnosis. Eligibility criteria included confirmed diagnosis of germ cell 
tumor (GCT), age <55 years at diagnosis, treatment with first-line platinum-based 
chemotherapy, no salvage chemotherapy, no radiotherapy, and no antecedent chemotherapy 
for another primary cancer. All participants were disease-free at the time of clinical 
evaluation and were undergoing routine follow-up at the participating site. The first 491 
consecutively enrolled TCS for whom funding was available to measure serum testosterone 
were included in this analysis. Participants in this analysis were similar to the first 1,214 
survivors enrolled in the Platinum Study16 in terms of age at testicular cancer diagnosis (P=.
81), age at clinical evaluation for the Platinum Study (P=.30), and other clinical and 
sociodemographic characteristics (supplemental eTable 1, available with this article at 
JNCCN.org). Data on the prevalence of metabolic syndrome and its risk factors in this 
cohort have been previously described.17
Assessments
Patient-Reported Health Outcomes and Lifestyle Behaviors—TCS completed a 
questionnaire regarding health outcomes, lifestyle behaviors, and current prescription 
medications with indications (including antihypertensive, diabetic, and lipid-lowering 
medications). Each of the following conditions was considered an AHO (definitions 
provided in supplemental eTable 2): hypercholesterolemia and on prescription medication, 
hypertension and on prescription medication, erectile dysfunction (ED), diabetes and on 
prescription medication, psychotropic prescription medications for anxiety and/or 
depression, CVD, peripheral vascular disease, thromboembolic disease, renal disease, 
peripheral neuropathy, Raynaud phenomenon, benign thyroid disease, tinnitus, hearing 
impairment, and problems with balance/vertigo/dizziness. Demographic information 
included age at cancer diagnosis and at clinical evaluation, race, education, employment, and 
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marital status. Smoking status was categorized as current, former, or never-smoker. Physical 
activity was reported as the average time per week engaged in various forms of exercise, 
using validated questionnaires.18 Moderate- and vigorous-intensity physical activity were 
defined as partid-pating in at least 1 activity per week with a metabolic equivalent (MET) of 
3 to <6 METs or ≥6 METs, respectively16,19,20
Data Collection From Medical Records
Study staff abstracted data according to a standardized protocol.15,16 Collected data included 
diagnosis date, histology, and site of GCT, and the name, dose, dates of administration, 
number of cycles, and cumulative dose for each cytotoxic drug. All data were entered into 
the eClinical system (www.eClinicalWorks.com), supported by the study coordinating 
center.
Clinical Evaluation
TCS underwent a brief physical examination, which included measurement of height and 
weight. Body mass index (BMI) was calculated as kg/m2. Blood samples were drawn and 
time of collection was recorded, and the samples were then frozen and shipped to the central 
laboratory. Serum levels of testosterone were measured using commercial assays. 
Hypogonadism was defined using the FDA definition (serum testosterone level ≤3.0 ng/
mL)21 or use of testosterone replacement therapy.
DNA Genotyping and Imputation—DNA was extracted from blood samples collected 
at clinical evaluation. SNPs were genotyped on the HumanOmniExpressExome-8 BeadChip 
Kit (Illumina, Inc.) at the RIKEN Center for Integrative Medical Sciences. Because the 
SNPs of interest are not called on this chip, we performed genotype imputation following 
standard quality control measures as previously described.22 Imputation was performed on 
the University of Michigan Imputation Server23 with the following parameters: 1000 
Genomes Phase 1 (version 3) SHAPEIT2 (no singletons) reference panel, SHAPEIT 
phasing, and the EUR (European) population. SNP calls were converted to risk allele dosage 
format.
Statistical Analyses
Data were summarized with median (ranges) for continuous variables and proportions for 
categorical variables in 2 TCS subgroups defined by the presence or absence of 
hypogonadism. Variables in the 2 groups were compared using the Pearson chi-square and 
2-sided Wilcoxon rank sum tests for categorical and continuous variables, respectively. To 
determine factors associated with hypogonadism in TCS, variables that were significantly 
different between the 2 groups with regard to clinical, sociodemographic, and other 
characteristics were included in the multivariable binary logistic regression analysis. 
Adjusted odds ratios (ORs), 95% CIs, and P values were reported. Cumulative number of 
risk alleles in SHBG was also included in the multivariable model due to evidence for its 
role in the determination of serum testosterone concentrations in the general male 
population.11 All statistical analyses were conducted using SAS 9.4 (SAS Institute Inc.). All 
tests were 2-sided, with P<.05 considered statistically significant.
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Results
Population Characteristics of TCS
A total of 491 TCS were assessed, with a median age at clinical evaluation of 38.2 years 
(Table 1). In all, 189 TCS (38.5%) met criteria for hypogonadism. TCS with hypogonadism 
were significantly older at clinical evaluation than those without hypogonadism (median age, 
42.6 vs 36.5 years; P<.001). Most TCS received bleomycin/etoposide/cisplatin (BEP; 
55.4%) or etoposide/cisplatin (EP; 32.4%), but hypogonadism prevalence did not differ by 
treatment regimen (P= .95) or cumulative dose of cisplatin or bleomycin (P=.99 and .56, 
respectively). TCS with hypogonadism had a significantly higher prevalence of being 
overweight or obese (83.1% vs 69.2%; P<.001), and were less likely to participate in 
vigorous-intensity physical activity (56.1% vs 72.5%; P<.001) compared with those without 
hypogonadism.
Factors Associated With Hypogonadism in TCS
In multivariable binary logistic regression analysis, age at clinical evaluation (OR, 1.42 per 
10-year increase in age; 95% CI, 1.10–1.83; P=.006) and being overweight (BMI, 25 to <30 
kg/m2; OR, 2.08; 95% CI, 1.18–3.66; P=.011) or obese (BMI, ≥30 kg/m2; OR, 2.36; 95% 
CI, 1.29–4.31; P= .005) were significantly associated with increased risk for hypogonadism 
(Table 2). Although significant in bivariate analysis, vigorous-intensity physical activity was 
only marginally associated with reduced hypogonadism risk (OR, 0.66; 95% CI, 0.41–1.04; 
P=.07) after adjusting for other independent variables in the model. TCS with 2 or 3 risk 
alleles had a trend for increased risk of hypogonadism compared with TCS with no or 1 risk 
allele in multivariable analysis (OR, 1.45; 95% CI, 0.95–2.24; P=.09).
Association Between Hypogonadism and AHOs
Among all 15 AHOs included in the survey, 28% of TCS with hypogonadism reported ≥4 
AHOs compared with 16% of those without hypogonadism (Figure 1), and TCS with 
hypogonadism were less likely to report no or only one AHO (35%) compared with those 
without (49%) (P=.002). Associations between specific AHOs and hypogonadism are shown 
in Table 3. Compared with TCS without hypogonadism, those with hypogonadism were 
significantly more likely to take medications for hypercholesterolemia (20.1% vs 6.0%; P<.
001), hypertension (18.5% vs 10.6%; P=.013), and ED (19.6% vs 11.9%; P=.018), with a 
marginal trend toward increased use of prescription medications for either diabetes (5.8% vs 
2.6%; P=.07) or anxiety/depression (14.8% vs 9.3%; P=.06). TCS with hypogonadism were 
also significantly more likely to report symptoms of moderate or severe peripheral 
neuropathy (30.7% vs 22.5%; P=.041) compared with those without hypogonadism. As 
expected, no associations were observed between hypogonadism and several of the AHOs, 
such as tinnitus and hearing loss.
Association of Genetic Variants in SHBG With Hypogonadism
We assessed the association of 2 SNPs (rs6258 and rs12150660) in the SHBG locus 
previously implicated in increased hypogonadism risk in the general population.11 SNPs 
rs12150660 and rs6258 showed, respectively, high imputation quality (R2, 0.99 and 0.87), 
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high call rate (>99.7% and >99.8%), and perfect Hardy-Weinberg equilibrium (P=.98 and .
97). Because rs6258 is a rare variant (minor allele frequency, 0.69%), there were no 
homozygous minor patients and only 7 heterozygous patients in the cohort. Both SNPs 
displayed effect sizes similar to those reported previously in the general population (rs6258: 
OR, 1.6; P=.5; rs12150660: OR, 0.79; P=.28). When the risk for hypogonadism was 
analyzed according to the cumulative number of risk alleles for rs12150660 (G) and rs6258 
(T) (Figure 2), OR per each additional risk allele was 1.26 (95% CI, 0.91–1.76; P for trend 
=.17).
Discussion
To date, this is the largest investigation of the prevalence of hypogonadism and associated 
AHOs among North American TCS after treatment with modern cisplatin-based 
chemotherapy. It is also the first series to investigate the influence of genetic variants in the 
SHBG gene on hypogonadism risk in TCS. At a median age of only 38 years at clinical 
evaluation, >38% of TCS had low testosterone levels or were on testosterone replacement 
therapy. Significant risk factors included increasing age and BMI. Although vigorous-
intensity physical activity appeared protective and genetic variants in SHBG may have 
influenced hypogonadism risk, results were of borderline significance.
Similar to findings in the general population24–28 and in European studies of TCS,29–34 TCS 
with hypogonadism in our study were more likely to report components of metabolic 
syndrome than TCS with normal testosterone levels. In particular, they were at least 3 times 
more likely to take medications for high cholesterol levels (P<.001) and almost twice as 
likely to take medications for high blood pressure (P=.013) and diabetes (P=.07). These 
observations may explain findings in previous studies that TCS treated with chemotherapy 
experience up to a 7-fold increased risk for CVD, with upswings in risk typically observed 
≥10 years after therapy.35–39 Because the median cohort follow-up time was <5 years, we 
have not yet observed an increase in cardiovascular events among TCS with hypogonadism, 
but long-term follow-up of all survivors is planned. The association between hypogonadism 
and peripheral neuropathy was unexpected and may represent a chance finding. However, 
we previously showed that peripheral sensory neuropathy among TCS is associated with 
weight gain adjusted for years since treatment (P=.004).40 Thus, it is possible that TCS with 
significant neuropathy may not be able to exercise adequately, and consequently develop 
obesity that increases hypogonadism risk, as it does among men in the general population.7 
The prevalence of metabolic syndrome in TCS and its risk factors have been reviewed in 
detail elsewhere.17
In our investigation, the cumulative dose of cisplatin did not correlate with the prevalence of 
hypogonadism. Other studies41,42 have reported a higher prevalence of hypogonadism in 
TCS who received higher doses of cisplatin. Because most patients in the current series 
(89.1%) received a cumulative cisplatin dose between 300 and 400 mg/m2, this may explain 
the lack of correlation observed.
Ohlsson et al11 recently performed a meta-analysis of genome-wide association data in 
14,429 men from 7 cohorts in the general population and identified 2 SNPs at the SHBG 
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locus as independently associated with serum testosterone concentration. In our study, these 
SNPs also appeared to affect testosterone concentration but were of borderline statistical 
significance. In addition, although the magnitude of influence of these genetic variants on 
serum testosterone concentration (OR, 1.26 per additional risk allele) in TCS was some-
what less than reported in the general population (OR, 1.62 per additional risk allele), the 
95% CIs overlapped substantially. In addition, it is possible that other genetic variants, 
possibly ones that predispose to testicular dysgenesis syndrome (eg, INSL3 and LGR8),43–45 
may be of higher importance in TCS. As pointed out by Ohlsson et al,11 the eventual clinical 
use of these genetic variants will require further investigation. A critical question is the 
extent to which these polymorphisms might also influence the eventual development of 
CVD, and not only mediate low testosterone levels. It is important to note that the 
prevalence of hypogonadism was substantially higher in our survivors (38.5%) compared 
with subjects included in the meta-analysis by Ohlsson et al11 (13.5%) (Figure 2). This is 
despite the fact that the median age of our TCS was only 38 years at the time of clinical 
evaluation compared with a mean age of 61.7 years for those included in Ohlsson et al.11 
This places TCS at risk of the complications of hypogonadism for many more decades than 
men without a history of testicular cancer.
Studies of the effect of testosterone replacement therapy on metabolic abnormalities and 
CVD risk in TCS are sparse. Investigations in middle-aged and highly functioning older men 
with no cancer history showed favorable effects on lipid metabolism, bone mineral density, 
muscle mass, and fat-free body mass.9,10 However, evidence regarding the effect of 
testosterone replacement on CVD risk has been conflicting,46 with one clinical trial showing 
an unexpected increase in adverse CVD events in older men treated with testosterone,47 but 
another series reporting no excess CVD events.48 A recent report from the Testosterone 
Trials (TTrials) group49 showed a significantly greater increase in coronary artery 
noncalcified plaque volume among older men with symptomatic hypogonadism treated with 
testosterone gel for 1 year compared with placebo.49 However, none of these trials47–49 was 
designed to prospectively assess adverse cardiovascular events, and moreover, these findings 
may not apply to considerably younger TCS. For young TCS with symptomatic 
hypogonadism, testosterone replacement should be considered, and future research is needed 
to stringently address both the benefits and risks of testosterone replacement therapy. Two 
studies that examine the effect of testosterone replacement versus placebo on CVD risk 
factors and various biomarkers have recently started recruiting TCS in Europe 
(ClinicalTrials.gov identifiers: NCT02991209 and NCT03339635). Although results of these 
trials may provide some insights, the duration of each is ≤12 months, and thus it is unlikely 
that they will be able to provide information on the risk of CVD outcomes.
Strengths and Limitations
Strengths of our study include the large number of patients, detailed medical chart 
abstraction, and evaluation of several risk factors for hypogonadism, including genetic 
variants. We also used a definition for hypogonadism that is clinically relevant and easily 
applicable to clinical practice. However, any cross-sectional design has potential limitations 
and does not allow us to infer causation either of evaluated risk factors to hypogonadism or 
of hypogonadism to associated AHOs. Although our investigation included many AHOs, by 
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design it was largely focused on cisplatin-related toxicities. Issues such as sexual 
dysfunction and fertility will be investigated in additional longitudinal follow-up of this 
cohort. Because blood samples were collected at routine clinic visits, serum testosterone 
levels were measured only once per patient and did not always occur in the morning as per 
the recommendation for testosterone testing. Although the SNPs of interest were imputed 
and not genotyped, they were in perfect linkage disequilibrium with a nearby genotyped 
SNP.
Conclusions
At a relatively young age, there is a high prevalence of hypogonadism among North 
American TCS treated with modern cisplatin-based chemotherapy. Major risk factors 
include increasing age and obesity. Hypogonadism was strongly associated with risk factors 
for CVD. The clinical value of assessing possible genetic variants in the role of 
hypogonadism requires further study before these are recommended for use in the clinic. In 
the meantime, TCS should be encouraged to maintain a normal body weight and a healthy 
lifestyle. Although there are currently no evidence-based guidelines, Bhasin et al50 
recommend that healthcare providers screen for hypogonadism by surveying TCS for the 
classic symptoms of hypogonadism (decreased energy, depressed mood, decreased sexual 
desire and performance, and night sweats)50 and prescribe testosterone replacement therapy 
to survivors who have low testosterone levels on 2 occasions and have symptoms related to 
low testosterone.
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Figure 1. 
Prevalence of total number of AHOs in TCS and other malignant germ cell tumors with or 
without hypogonadism. TCS with hypogonadism were more likely to report more AHOs 
compared with those without. Chi-square test, P=.002.
Abbreviations: AHO, adverse health outcome; TCS, testicular cancer survivors.
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Figure 2. 
Prevalence of hypogonadism per cumulative number of risk alleles in SHBG in the Platinum 
Study versus Ohlsson et al.11 Percentage of men with hypogonadism among 404 survivors 
of testicular cancer compared with 5,434 men in the general population included in a meta-
analysis by Ohlsson et al,11 according to the number of combined risk alleles for 
rs12150660 (G) and rs6258 (T) in SHBG. No survivor in the Platinum Study had 4 risk 
alleles and only 5 survivors had 3 risk alleles. Odds ratio (OR) per each additional risk allele 
was 1.26 (95% CI, 0.91–1.76; P for trend = .17). This compares with an OR of 1.62 per risk 
allele in the general population (95% CI, 1.41–1.86; P for trend =6.5×10−12).
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Table 2.
Multivariable Binary Logistic Regression Analysis of Potential Risk Factors for Hypogonadism in TCS and 
Other Malignant GCTs
Variable OR 95% CI P Valuea
Age at clinical evaluation, per 10 y 1.42 1.10–1.83 .006
Marital status
 Married/Living as married – – Ref
 Not married 0.79 0.50–1.25 .31
Tumor histology
 Seminoma – – Ref
 Nonseminoma/Mixed 0.79 0.48–1.31 .36
Body mass index
 <25 kg/m2 – – Ref
 25 to <30 kg/m2 2.08 1.18–3.66 .011
 ≥30 kg/m2 2.36 1.29–4.31 .005
Vigorous-intensity physical activity (≥6 METs)
 No – – Ref
 Yes 0.66 0.41–1.04 .07
Cumulative number of risk alleles in rs6258 and rs12150660 (SHBG)
 0 or 1 risk alleles – – Ref
 2 or 3 risk alleles 1.45 0.95–2.24 .09
Abbreviations: GCT, germ cell tumor; METs, metabolic equivalents; OR, odds ratio; TCS, testicular cancer survivors.
a
Bold indicates ORs with P<.05. For the multivariable binary logistic regression analyses, 88 survivors were excluded due to unavailable data for 
≥1 variables.
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